1 (Image 1)
Finzala Kit
Product Images NDC 0093-8210
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finzala (NDC 0093-8210). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
1 (Image 2)
1 (Image 3)
This is a graph showing the concentration of Norethindrone in pg/mL over time in hours. The concentration ranges from 4000 pg/mL to 14000 pg/mL, with time increasing from 12 to 30 hours.*
1 (Image 4)
1 (Image 5)
This text is describing different methods of birth control and their effectiveness in preventing pregnancy, ranging from less than 1 pregnancy per 100 women per year to 85 or more pregnancies per 100 women per year. The listed methods include injections, intrauterine devices, sterilization, birth control pills, a skin patch, a vaginal ring with hormones, condoms, a diaphragm, no sex during the most fertile days of the monthly cycle, spermicide, withdrawal, and the lack of birth control altogether.*
1 (Image 6)
This is a product description for birth control pills. The package contains pills for four weeks, with labels for each day of the week. The pills are only to be stored in a controlled room temperature of 68°F to 77°F. The package is not child-resistant, and must be kept out of reach of children. The pills contain norethindrone acetate and ethinyl estradiol, and are for daily oral use. There are different start options depending on the user's menstrual cycle, and the pills should be taken from left to right each week.*
1 (Image 7)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
